Streetbeat News

Regulatory

BMY

The Committee for Medicinal Products for Human Use (CHMP) has recommended a change to the marketing authorization for Abecma, extending its indication to treat adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 12:14 pm

APLS

Apellis Pharmaceuticals received a negative opinion from the Committee for Medicinal Products for Human Use (CHMP) regarding its application for Pegcetacoplan for the treatment of geographic atrophy (GA) in the European Union. The company plans to request a re-examination of the application.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 12:11 pm

AAPL

Apple Inc. has begun beta testing iOS 17.4, which introduces app sideloading but only for EU users in response to the EU's Digital Markets Act. The feature allows alternative app stores to operate under strict conditions. Despite this, JP Morgan predicts the change will not significantly affect Apple's App Store revenue, as the EU represents only 6% of that revenue and a new fifty-cent fee could offset commission reductions.

Portfolio Pulse from Ananya Gairola

January 26, 2024 | 11:56 am

PM

Philip Morris International issued a clarification regarding its marketing practices, specifically addressing the facts related to ZYN nicotine pouches. The company emphasized its commitment to responsible marketing and adherence to regulations.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 11:22 am

VOD

The UK Competition and Markets Authority (CMA) has initiated a Phase 1 investigation into the proposed merger between Vodafone and Three. The CMA will spend up to 40 working days to assess the potential impacts of the deal on competition.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 10:21 am

VNDA

Vanda Pharmaceuticals Inc. has received a notice of allowance from the U.S. Patent and Trademark Office for a patent application related to PONVORY® (ponesimod), which is used in the treatment of multiple sclerosis. The patent covers methods for reducing clinical management events and reinitiating treatment after missed doses, with an anticipated expiration date of October 10, 2042. Vanda plans to list the patent in the FDA's Orange Book upon issuance.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 7:21 am

RHHBY

Roche's Genentech has announced new long-term data for Vabysmo, showing sustained improvements in retinal drying and vision for patients with Retinal Vein Occlusion (RVO). The data indicates that up to 60% of patients could extend treatment intervals to three or four months. Detailed results from two global Phase III RVO studies will be presented at the Angiogenesis, Exudation, and Degeneration 2024 conference. Vabysmo is approved in the U.S. for RVO and in over 90 countries for wet AMD and DME.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 6:33 am

WDC

Worldcoin is redesigning its Orb device to be more user-friendly and aesthetically similar to Apple products, as revealed by CEO Alex Blania. The new design is expected in the first half of the year. The Orb scans irises to create a unique 'World ID' for accessing Worldcoin's applications. Despite polarized opinions on the device, Worldcoin has seen significant user growth, with 190,000 new users in the last week, totaling 3.13 million. The company has raised $250 million from investors like a16z and Bain Capital Crypto. OpenAI's CEO Sam Altman, a co-founder of Worldcoin, remains committed to the project amidst regulatory scrutiny in the U.K. and Germany. Worldcoin's cryptocurrency, WDC, is up 5.23% at $0.0079.

Portfolio Pulse from Mehab Qureshi

January 26, 2024 | 4:54 am

AAPL

JPM

JP Morgan Chase & Co. believes that Apple Inc.'s revenue will not be significantly impacted by the EU's new Digital Markets Act, despite Apple reducing its App Store commission and introducing a new fee. The EU accounts for only 6% of Apple's App Store revenue, and the new fifty-cent fee is expected to offset the commission cut. These changes are part of Apple's compliance with EU competition law and will take effect with the release of iOS 17.4.

Portfolio Pulse from Ananya Gairola

January 26, 2024 | 3:42 am

BTC-USD

Vivek Ramaswamy, an entrepreneur, voiced concerns about the threats to personal financial liberty posed by a Central Bank Digital Currency (CBDC). He believes a CBDC could enable the government to freeze assets of dissenters, citing examples from China and Canada. Ramaswamy praised former President Donald Trump for being open to these concerns and publicly opposing CBDCs. Trump has reiterated his stance against CBDCs, emphasizing the protection of individual financial freedom. Meanwhile, Bitcoin (BTC) saw a slight increase in its price.

Portfolio Pulse from Mehab Qureshi

January 26, 2024 | 3:38 am